Peptide record

TPDB06278

Antibacterial Anticancer Toxicity standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06278
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 11-aa standard-residue multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
WLRRIKAWLRR
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C73H120N26O12
NDCEQGHMFPSTYV
R
1553.92
12.88
5
0
6
+5
4.00
-0.891
115.45
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
11000
7.08
0
Residue Composition
number
1
A
4
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
2
L
1
K
0
M
0
F
0
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 2 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
11 reviewed residue count
C73H120N26O12 sequence-only estimate (linear, free termini)
1553.92 sequence-only estimate (linear, free termini)
12.88 sequence-only estimate (linear, free termini)
+5 sequence-only estimate (linear, free termini)
4.00 sequence-only estimate (linear, free termini)
-0.891 sequence-only estimate (linear, free termini)
Evidence Records 5 records
Evidence 1 Activity

Activity

MIC
Antibacterial
8-32 µM

Target

Staphylococcus aureus MSSA or MRSA many strains

Source & Reference

NA

Other

active against S. aureus MSSA or MRSA many strains (MIC 8-32 uM) and S. epidermidis (MIC 8 uM). Also antibiofilms.
Evidence 2 Activity

Activity

MIC
Antibacterial
8 µM

Target

Staphylococcus epidermidis

Source & Reference

NA

Other

active against S. aureus MSSA or MRSA many strains (MIC 8-32 uM) and S. epidermidis (MIC 8 uM). Also antibiofilms.
Evidence 3 Activity

Activity

IC50
Toxicity
128 µM
Cytotoxic
IC50 | 128 | µM | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Antibacterial Activity of Novel Cationic Peptides against Clinical Isolates of Multi-Drug Resistant Staphylococcus pseudintermedius from Infected Dogs. | PLoS One | 2014
Evidence 4 Activity

Activity

IC50
Toxicity
256 µM
Cytotoxic
IC50 | 256 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Antibacterial Activity of Novel Cationic Peptides against Clinical Isolates of Multi-Drug Resistant Staphylococcus pseudintermedius from Infected Dogs. | PLoS One | 2014
Evidence 5 Activity

Activity

10% Hemolysis
Toxicity
300 µM
Hemolytic Cytotoxic
10% Hemolysis | 300 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides. | Antimicrob Agents Chemother | 2014